HHS says it may revisit policy for anti-obesity drugsnews2025-04-07T20:08:01+00:00April 7th, 2025|Endpoints News|
FDA cuts hit drug ad review office, in seeming contradiction with Kennedy’s goalsnews2025-04-01T19:00:29+00:00April 1st, 2025|Endpoints News|
J&J touts new survival data for lung cancer combonews2025-03-26T16:01:33+00:00March 26th, 2025|Endpoints News|
Novo Nordisk slashes Wegovy price for patients without insurance news2025-03-05T16:52:07+00:00March 5th, 2025|Endpoints News|
Misleading promotion lands NJ drugmaker a letter from FDAnews2025-03-04T19:45:44+00:00March 4th, 2025|Endpoints News|
Eli Lilly expands Zepbound single-dose vial options at lower pricenews2025-02-25T11:45:31+00:00February 25th, 2025|Endpoints News|
J&J’s combo beats Tagrisso on survival in first-line lung cancernews2025-01-07T13:00:35+00:00January 7th, 2025|Endpoints News|
Drugs are approved and available faster in US than most of EU, data shownews2024-12-11T18:30:47+00:00December 11th, 2024|Endpoints News|
Novartis bolsters Fabhalta data in competition with AstraZenecanews2024-12-06T17:45:30+00:00December 6th, 2024|Endpoints News|
Novartis to cut 139 jobs in NJ as part of commercial refocusnews2024-11-27T16:54:45+00:00November 27th, 2024|Endpoints News|
